Effect of Tirzepatide on Diabetic Peripheral Sensorimotor Neuropathy

Sponsor
Post Graduate Institute of Medical Education and Research, Chandigarh
Study ID
NCT07706088
Phase
PHASE4
Status
Not Yet Recruiting

Notify me when recruiting opens

Save your spot on the interest list for this study. We'll keep your details with this study so our team can follow up when recruiting opens.

Not yet recruiting

Add your contact details and location so we can keep your interest tied to this study.

Conditions

  • Diabete Mellitus
  • Neuropathy, Small Fiber

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

Study Details

Tirzepatide is a dual agonist of GLP-1 Receptor and the GIP receptor, producing substantial improvement in glycaemic control, weight reduction and insulin sensitivity. Beyond its metabolic effects, incretin signalling has demonstrated neuroprotective and neurotropic properties, including activation of intracellular pathways that enhance neuronal survival and regeneration. Using tirzapatide for diabetic sensorimotor peripheral neuropathy and assessing with CCM / NCS and BDNF will represent three complementary aspects of nerve regeneration: metabolic control, structural nerve repair and neurotrophic signalling.

Key Dates

First listed
Jul 15, 2026
Start date
Jul 31, 2026
Status verified
Jul 2026
Primary completion
Jul 1, 2028
Completion
Jul 1, 2028

Study Design

Enrollment
40 participants (estimated)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Experimental: patients with diabetic peripheral neuropathy to receive standard of care including tirzepatide
    tirzepatide drug being given to diabetic patients with peripheral neuuropathy
  • Active Comparator: diabetic patients recieving standard care without use of tirzepatide
    all standard care except tirzepatide

Primary Outcome Measure

To assess the percent change in CNFD compared to baseline [ Time Frame: 6 months ]

Related Studies